Billin, Andrew N.

Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial

Patel, K., Harrison, S. A., Elkhashab, M., Trotter, J. F., Herring, R., Rojter, S. E., Kayali, Z., Wong, V. W., Greenbloom, S., Jayakumar, S., et al. (2020) · Hepatology

Liver Disease Diagnosis and TreatmentHepatitis C virus research

Cited by 347

Glucose sensing by MondoA:Mlx complexes: a role for hexokinases and direct regulation of thioredoxin-interacting protein expression

Stoltzman, C. A., Peterson, C. W., Breen, K. T., Muoio, D. M., Billin, A. N., & Ayer, D. E. (2008) · Proceedings of the National Academy of Sciences

Metabolism, Diabetes, and CancerCancer, Hypoxia, and Metabolism

Cited by 283

An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)

Vacca, M., Kamzolas, I., Harder, L. M., Oakley, F., Trautwein, C., Hatting, M., Ross, T., Bernardo, B., Oldenburger, A., Hjuler, S. T., et al. (2024) · Nature Metabolism

Liver Disease Diagnosis and TreatmentDiet, Metabolism, and Disease

Cited by 262

Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial

Alkhouri, N., Herring, R., Kabler, H., Kayali, Z., Hassanein, T., Kohli, A., Huss, R. S., Zhu, Y., Billin, A. N., Damgaard, L. H., et al. (2022) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentHepatitis C virus research

Cited by 230

β-Catenin–Histone Deacetylase Interactions Regulate the Transition of LEF1 from a Transcriptional Repressor to an Activator

Billin, A. N., Thirlwell, H., & Ayer, D. E. (2000) · Molecular and Cellular Biology

Wnt/β-catenin signaling in development and cancerHistone Deacetylase Inhibitors Research

Cited by 216

Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis

Mózes, F. E., Lee, J. A., Vali, Y., Alzoubi, O., Staufer, K., Trauner, M., Paternostro, R., Stauber, R. E., Holleboom, A. G., van Dijk, A.-M., et al. (2023) · The Lancet Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentLiver Disease and Transplantation

Cited by 214

Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis

Loomba, R., Huang, D. Q., Sanyal, A. J., Anstee, Q. M., Trauner, M., Lawitz, E. J., Ding, D., Ma, L., Jia, C., Billin, A., et al. (2023) · Gut

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 110

The AMPK/p27Kip1 Axis Regulates Autophagy/Apoptosis Decisions in Aged Skeletal Muscle Stem Cells

White, J. P., Billin, A. N., Campbell, M. E., Russell, A. J., Huffman, K. M., & Kraus, W. E. (2018) · Stem Cell Reports

Muscle Physiology and DisordersMetabolism, Diabetes, and Cancer

Cited by 104

Identification and Characterization of 4-Chloro-N-(2-{[5-trifluoromethyl)-2-pyridyl]sulfonyl}ethyl)benzamide (GSK3787), a Selective and Irreversible Peroxisome Proliferator-Activated Receptor δ (PPARδ) Antagonist

Shearer, B. G., Wiethe, R. W., Ashe, A., Billin, A. N., Way, J. M., Stanley, T. B., Wagner, C. D., Xu, R. X., Leesnitzer, L. M., Merrihew, R. V., et al. (2010) · Journal of Medicinal Chemistry

Peroxisome Proliferator-Activated ReceptorsComputational Drug Discovery Methods

Cited by 78

AI-based automation of enrollment criteria and endpoint assessment in clinical trials in liver diseases

Iyer, J. S., Juyal, D., Le, Q., Shanis, Z., Pokkalla, H., Pouryahya, M., Pedawi, A., Stanford-Moore, S. A., Biddle-Snead, C., Carrasco-Zevallos, O., et al. (2024) · Nature Medicine

Liver Disease Diagnosis and TreatmentArtificial Intelligence in Healthcare and Education

Cited by 54

NAFLD and NASH biomarker qualification in the LITMUS consortium – Lessons learned

Rasmussen, D. G. K., Anstee, Q. M., Torstenson, R., Golding, B., Patterson, S. D., Brass, C., Thakker, P., Harrison, S., Billin, A. N., Schuppan, D., et al. (2023) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentStatistical Methods in Clinical Trials

Cited by 41

Peptide-based urinary monitoring of fibrotic nonalcoholic steatohepatitis by mass-barcoded activity-based sensors

Cazanave, S. C., Warren, A. D., Pacula, M., Touti, F., Zagorska, A., Gural, N., Huang, E. K., Sherman, S., Cheema, M., Ibarra, S., et al. (2021) · Science Translational Medicine

Liver Disease Diagnosis and TreatmentAdvanced Proteomics Techniques and Applications

Cited by 23

A Fibrosis-Independent hepatic transcriptomic signature identifies drivers of disease progression in primary sclerosing cholangitis

Gindin, Y., Chung, C., Jiang, Z., Zhou, J. Z., Xu, J., Billin, A. N., Myers, R. P., Goodman, Z., Landi, A., Houghton, M., et al. (2021) · Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 23